Cargando…
The Third Generation Anti-HER2 Chimeric Antigen Receptor Mouse T Cells Alone or Together With Anti-PD1 Antibody Inhibits the Growth of Mouse Breast Tumor Cells Expressing HER2 in vitro and in Immune Competent Mice
Chimeric Antigen Receptor (CAR)-T cells have great efficacy against CD19(+) leukemia but little success for solid tumors. This study explored the effectiveness of third generation anti-HER2 CAR-T cells alone or in combination with anti-PD1 antibody on breast tumor cells expressing HER2 in vitro and...
Autores principales: | Li, Panyuan, Yang, Lingcong, Li, Tong, Bin, Shufang, Sun, Bohao, Huang, Yuting, Yang, Kaiyan, Shan, Daming, Gu, Haihua, Li, Hongzhi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381237/ https://www.ncbi.nlm.nih.gov/pubmed/32766150 http://dx.doi.org/10.3389/fonc.2020.01143 |
Ejemplares similares
-
Mouse models and anti-HER2 therapies
por: Hanker, Ariella B., et al.
Publicado: (2013) -
Defucosylated mouse-dog chimeric anti-HER2 monoclonal antibody exerts antitumor activities in mouse xenograft models of canine tumors
por: Suzuki, Hiroyuki, et al.
Publicado: (2022) -
Targeting Androgen Receptor in Treating HER2 Positive Breast Cancer
por: He, Licai, et al.
Publicado: (2017) -
From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer
por: Sun, Jiangang, et al.
Publicado: (2022) -
Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
por: Yang, Liu, et al.
Publicado: (2022)